Studies of cost/effectiveness of pharmacological and psychological treatment of anxiety disorders: A literature review;Les études de coûts-efficacité des traitements pharmacologiques et psychologiques des troubles anxieux: Une recension des écrits

Sante Mentale au Quebec

Volumn 35, Issue 1, 2010, Pages 129-152

  Poirier Bisson, Joannie ^a   Roberge, Pasquale ^b   Marchand, André ^a   Grégoire, Rachel ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649796075     PISSN: 03836320     EISSN: 17083923     Source Type: Journal    
DOI: 10.7202/044801ar     Document Type: Review

References (34)

1. Agence canadienne des médicaments et des technologies de la santé, 2006, Lignes directrices de l'évaluation économique des technologies de la santé au Canada, 3e édition, Ottawa.
2. Association des psychiatres du Canada, 2006, Guide de pratique clinique: Traitement des troubles anxieux, La Revue canadienne de psychiatrie, 51, supplément 2, 1s-97s.
3. Baldwin, D. S., Anderson, I. M, Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T, Den Boer, J. A., Fineberg, N.A., Knapp, M., Scott, J., Wittchen, H. U, 2005, Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for psychopharmacology, Journal of Psychopharmacology, 19, 6, 567-596.
4. Barlow, D. H., Gorman, J. M., Shear, M. K., Woods, S.W., 2000, Cognitivebehavioral therapy, imipramine, or their combination for panic disorder. A randomized controlled trial, JAMA, 283, 19, 2529-2536.
5. Bower, P., Richards, D., Lovell, K., 2001, The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review, British Journal of General Practice, 51, 471, 838-845.
6. Briggs, A. H., 2001, A Bayesian approach to stochastic cost-effectiveness analysis, International Journal of Technology Assessment in Health Care, 17, 1, 69-82.
7. Cavanagh, K., Shapiro, D. A., 2004, Computer treatment for common mental health problems, Journal of Clinical Psychology, 60, 3, 239-251.
8. Cochrane Effective Practice and Organisation of Care Review Group (EPOC), 2002, http://www.epoc.cochrane.org/en/handsearchers.html, consulté le 24 septembre 2008.
9. Drummond, M. F., O'Brien, B., Stoddart, G. L., Torrance, G. W., 1997, Methods for the Economic Evaluation of Health Care Programmes, 2nd edition, Oxford University Press, New York.
10. Duhoux, A., Fournier, L., Nguyen, C., Roberge, P., Beveridge, R., sous presse, Guideline concordance of treatment for depressive disorders in Canada, Social Psychiatry and Psychiatric Epidemiology.
11. Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. R., Ballenger, J. C., Fyer, A. J., 1999, The economic burden of anxiety disorders in the 1990s, The Journal of Clinical Psychiatry, 60, 7, 427-435.
12. Hoch, J. S., Smith, M. W., 2006, A guide to economic evaluation: methods for cost-effectiveness analysis of person-level data, Journal of Traumatic Stress, 19, 6, 787-797.
13. Issakidis, C., Andrews, G., 2002, Service utilisation for anxiety in an Australian community sample, Social Psychiatry And Psychiatric Epidemiology, 37, 4, 153-163.
14. Issakidis, C., Sanderson, K., Corry, J., Andrews, G., Lapsley, H., 2004, Modelling the population cost-effectiveness of current and evidencebased optimal treatment for anxiety disorders, Psychological Medicine, 34, 1, 19-35.
15. Kaltenthaler, E., Shackley, P., Stevens, K., Beverley, C., Parry, G., Chilcott, J., 2002, A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety, Health Technology Assessment, 6, 22, 1-89.
16. Katon, W., Russo, J., Sherbourne, C., Stein, M. B., Craske, M., Fan, M.-Y., Roy-Byrne, P., 2006, Incremental cost-effectiveness of a collaborative care intervention for panic disorder, Psychological Medicine, 36, 3, 353-363.
17. Leon, A. C., Portera, L., Weissman, M. M., 1995, The social costs of anxiety disorders, British Journal of Psychiatry, Supplement, 27, 19-22.
18. Marchand, A., Germain, V., Reinharz, D., Mainguy, N., Landry, P., 2004, Analyse des coûts et de l'efficacité d'une psychothérapie pour le Trouble panique avec agoraphobie versus un traitement combinant la pharmacothérapie et la psychothérapie, Santé mentale au Québec, 29, 2, 201-220.
19. McCrone, P., Knapp, M., Proudfoot, J., Ryden, C., Cavanagh, K., Shapiro, D.A., Ilson, S., Gray, J. A., Goldberg, D., Mann, A., Marks, I., Everitt, B., Tylee, A., 2004, Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial, British Journal of Psychiatry, 185, 55-62.
20. McHugh, R.K., Otto, M.W., Barlow, D.H., Gorman, J.M., Shear, M.K., Woods, S.W., 2007, Cost-efficacy of individual and combined treatments for panic disorder, Journal Of Clinical Psychiatry, 68, 7, 1038-1044.
21. Ministère de la santé et des services sociaux (MSSS), 2005, Plan d'action en santé mentale 2005-2010: La force des liens, Québec.
22. Murray, C. J. L., Evans, D. B., Acharya, A., Baltussen, R. M., 2000, Development of WHO guidelines on generalized cost-effectiveness analysis, Health Economics, 9, 3, 235-251.
23. Netten, A., Curtis, l., 2000, Units Costs of Health and Social Care, Canterbury, PSSRU.
24. Organisation mondiale de la santé, Rapport sur la santé dans le monde 2001, La santé mentale, nouvelle conception, nouveaux espoirs, Organisation mondiale de la santé.
25. Otto, M. W., Pollack, M. H., Maki, K. M., 2000, Empirically-supported treatments for panic disorder: costs, benefits, and stepped care, Journal of Consulting and Clinical Psychology, 68, 4, 556-563.
26. Roberge, P. Marchand, A., Reinharz, D., Savard, P., 2008, Cognitivebehavioral treatment for panic disorder with agoraphobia., A randomized controlled trial and cost-effectiveness analysis, Behavior Modification, 32, 3, 333-351.
27. Roy, S., Madhavan, S. S., 2008, Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions, Pharmacoeconomics, 26, 4, 281-296.
28. Roy-Byrne, P. P., Wagner, A. W., Schraufnagel, T. J., 2005, Understanding and treating panic disorder in the primary care setting, Journal Of Clinical Psychiatry, 66, Suppl 4, 16-22.
29. Somers, J. M., Goldner, E. M., Waraich, P., Hsu, L., 2006, Prevalence and incidence studies of anxiety disorders: a systematic review of the literature, Canadian Journal of Psychiatry, 51, 2, 100-113.
30. Stant, A. D., Ten Vergert, E. M., den Boer, P. C. A. M., Wiersma, D., 2008, Cost-effectiveness of cognitive self-therapy in patients with depression and anxiety disorders, Acta Psychiatrica Scandinavica, 117, 1, 57-66.
31. Stein, M. B., Sherbourne, C. D., Craske, M. G., Means-Christensen, A., Bystritsky, A., Katon, W., Sullivan, G., Roy-Byrne, P. P., 2004, Quality of care for primary care patients with anxiety disorders, American Journal of Psychiatry, 161, 12, 2230-2237.
32. van Roijen, L.H., van Straten, A., Al, M., Rutten, F., Donker, M., 2006, Cost-utility of brief psychological treatment for depression and anxiety, British Journal of Psychiatry, 188, 323-329.
33. Wang, P. S., Berglund, P., Kessler, R. C., 2000, Recent care of common mental disorders in the United States: prevalence and conformance with evidence-based recommendations, Journal of General Internal Medicine, 15, 5, 284-292.
34. Young, A. S., Klap, R., Sherbourne, C. D., Wells, K. B., 2001, The quality of care for depressive and anxiety disorders in the United States, Archives of General Psychiatry, 58, 1, 55-61.